West German Prostate Center cooperates with the Charité in Berlin
Patients with localized prostate carcinoma estimate the healing success of surgery, radiation or active surveillance. What influences the decision for the type of treatment? In a current study, the research group led by PD Dr. Friederike Kendel from the Institute of Medical Psychology at the Charité is investigating these questions. Together with other institutes, the West German Prostate Center supports the so-called COPCa study ("Coping with low risk prostate cancer").
Around 67,000 men in Germany are confronted with the diagnosis of prostate cancer every year. Thanks to significantly improved early detection possibilities, especially since the introduction of the PSA test, more than 90 percent of all tumours are now detected at an early and therefore mostly curable stage. If the tumour is limited to the prostate, there are several treatment options available to the affected person,"explains Dr. Stephan Neubauer from the West German Prostate Center in Cologne: internal radiation (brachytherapy), external radiation or radical surgery. In men with low-risk carcinoma, it is even possible to monitor the tumour closely (Active Surveillance, AS). Which treatment strategy is the right one for which patient must always be decided individually,"the urologist continues.
In addition to the type of tumour, accompanying illnesses and age, however, the patient's personal reasons and preferences also play a role in the choice of therapy. PD Dr. Friederike Kendel from the Institute of Medical Psychology at the Charité is dedicated to this aspect. Together with several cooperation partners, including the Westdeutsche Prostatazentrum in Cologne, the scientist is investigating how the decision making process of the affected person is influenced and which side effects and strains are associated with the respective treatment.
Conditions of Participation for the COPCa - Study
Men with a diagnosed low-risk prostate cancer are interviewed on the basis of a detailed questionnaire on treatment decision, health status, perception and treatment of the disease. The survey will be repeated after 6,12 and 18 months. The condition for participation is that the men are not older than 75 years of age and that the diagnosis date is no longer than 3 months ago. If the patient has decided to undergo invasive therapy such as radiotherapy or surgery, this should not have started yet.
Our aim is to use the COPCa study to help provide patients with transparent information on the various treatment options for low-risk prostate cancer and their quality of life. This has always been a major concern of the West German Prostate Center:"Only those who have fully understood their disease and the various treatment options can make an optimal therapy decision," emphasizes Dr. Neubauer.
If you would like to participate in the study, please contact us or contact us directly - by phone or e-mail at the Charité: Monday and Thursday, 1 p. m. - 4 p. m. on 030/450529168 or at copca@charité.de